Chemistry:Dalpiciclib
From HandWiki
Dalpiciclib is a drug for the treatment of various forms of cancer.[1]
In China, dalpiciclib is approved for use in combination with fulvestrant for treatment of HR-positive, HER2-negative recurrent, or metastatic breast cancer in patients who have progressed after previous endocrine therapy.[2]
Dalpicicilib is a CDK inhibitor that targets the CDK4 and CDK6 isoforms.[3]
References
- ↑ "Dalpiciclib in advanced breast cancer". The Lancet. Oncology 24 (6): 578–579. June 2023. doi:10.1016/S1470-2045(23)00228-0. PMID 37269836.
- ↑ "Dalpiciclib in Combination with Letrozole or Anastrozole Significantly Improved Progression-free Survival in Systemic Treatment-naive, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer". https://www.hengrui.com/en/media/detail-252.html.
- ↑ "The emerging CDK4/6 inhibitor for breast cancer treatment". Molecular and Cellular Pharmacology 13 (3): 9–12. 2021. PMID 35251463.
 |  |
